The prohibition of drugs through sumptuary legislation or religious law is a common means of attempting to prevent the recreational use of certain intoxicating substances.
The Misuse of Drugs Act 1971 is an act of the Parliament of the United Kingdom. It represents action in line with treaty commitments under the Single Convention on Narcotic Drugs, the Convention on Psychotropic Substances, and the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.
Cannabis classification in the United Kingdom refers to the class of drugs, as determined by the Misuse of Drugs Act 1971, that cannabis is placed in. Between 1928 and 2004 and since 2009, it has been classified as a class B drug. From 2004 to 2009, it was a class C drug. At present, it is a class B, with very limited exceptions.
The Misuse of Drugs Act 1975 is a New Zealand drug control law that classifies drugs into three classes, or schedules, purportedly based on their projected risk of serious harm. However, in reality, classification of drugs outside of passing laws, where the restriction has no legal power, is performed by the governor-general in conjunction with the Minister of Health, neither of whom is actually bound by law to obey this restriction.
Desoxypipradrol, also known as 2-diphenylmethylpiperidine (2-DPMP), is a drug developed by Ciba in the 1950s which acts as a norepinephrine-dopamine reuptake inhibitor (NDRI).
These drugs are known in the UK as controlled drug, because this is the term by which the act itself refers to them. In more general terms, however, many of these drugs are also controlled by the Medicines Act 1968, there are many other drugs which are controlled by the Medicines Act but not by the Misuse of Drugs Act, and some other drugs are controlled by other laws.
The Drug Equality Alliance is a non-profit organisation based in the United Kingdom whose mission statement is:
[...] It is made to transform the "War on Some People who use Some Drugs" from its subjective historical and cultural roots into a rational and objective legal regulatory framework that secures equal rights and equal protection to all those who are concerned with dangerous or otherwise harmful drugs. Our mission is to use domestic and international legal jurisdictions to interrogate the law and its application to those who produce, commerce, possess and consume such drugs.
The production, distribution, and sale of methamphetamine is restricted or illegal in many jurisdictions.
Drugs considered addictive or dangerous in the United Kingdom are called "controlled substances" and regulated by law. Until 1964 the medical treatment of dependent drug users was separated from the punishment of unregulated use and supply. Under this policy drug use remained low; there was relatively little recreational use and few dependent users, who were prescribed drugs by their doctors as part of their treatment. From 1964 drug use was decreasingly criminalised, with the framework still in place as of 2014 largely determined by the Misuse of Drugs Act.
The Controlled Drugs (Penalties) Act 1985 is an Act of the Parliament of the United Kingdom. It amended the Misuse of Drugs Act 1971 and the Customs and Excise Management Act 1979 to increase the maximum penalty for importing, producing or supplying Class A drugs, or possessing them with intent to supply, from 14 years to life imprisonment.
25CN-NBOMe is a derivative of the phenethylamine 2C-CN. It acts in a similar manner to related compounds such as 25I-NBOMe, which are potent agonists at the 5HT2A receptor.
The Intoxicating Substances (Supply) Act 1985 was a UK Act of Parliament. It made it an offence for people to supply substances that are not controlled by the Misuse of Drugs Act 1971 to people under 18 years of age when it is likely that the substance could be inhaled for the purpose of intoxication. The legislation was drafted in the 1980s due to concern over solvent abuse but was used in the 2010s to prosecute those selling designer drugs that are inhaled. The Act was repealed and replaced by the Psychoactive Substances Act 2016.
Nitrazolam is a triazolobenzodiazepine (TBZD) , which are benzodiazepine (BZD) derivatives, that has been sold online as a designer drug.
The Psychoactive Substances Act 2016 is an Act of the Parliament of the United Kingdom intended to restrict the production, sale and supply of a new class of psychoactive substances often referred to as "legal highs". The bill was given Royal Assent on 28 January 2016, and came into force on 26 May 2016 across the entire United Kingdom.
Hexedrone is a stimulant of the substituted cathinone class which has been sold as a designer drug. Through analysis of the Structure-Activity Relationships in similar cathinones such as MDPV, hexedrone is believed to be a norepinephrine–dopamine reuptake inhibitor.
25C-NB3OMe is a derivative of the phenethylamine hallucinogen 2C-C, which acts as a highly potent partial agonist for the human 5-HT2A receptor.
25I-NB4OMe is a derivative of the phenethylamine hallucinogen 2C-I, which acts as a highly potent partial agonist for the human 5-HT2A receptor.
25C-NB4OMe is a derivative of the phenethylamine hallucinogen 2C-C, which acts as a highly potent partial agonist for the human 5-HT2A receptor.
25I-NB3OMe is a derivative of the phenethylamine hallucinogen 2C-I, which acts as a highly potent partial agonist for the human 5-HT2A receptor.
Ethylpropyltryptamine is a rarely encountered psychedelic substance from the tryptamine class, which makes it structurally related to DMT, MET, DET, and DPT.
